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Objectives: High-quality clinical evidence is most often lacking when novel high-risk devices enter the European market. At the same time, a randomized controlled trial (RCT) is often initiated as a
requirement for obtaining market access in the US. Should coverage in Europe be postponed until RCT data are available? We studied the premarket clinical evaluation of innovative high-risk medical
devices in Europe compared with the US, and with medicines, where appropriate.
Methods: The literature and regulatory documents were checked. Representatives from industry, Competent Authorities, Notified Bodies, Ethics Committees, and HTA agencies were consulted. We also
discuss patient safety and the transparency of information.
Results: In contrast to the US, there is no requirement in Europe to demonstrate the clinical efficacy of high-risk devices in the premarket phase. Patients in Europe can thus have earlier access to a
potentially lifesaving device, but at the risk of insufficiently documented efficacy and safety. Variations in the stringency of clinical reviews, both at the level of Notified Bodies and Competent
Authorities, do not guarantee patient safety. We tried to document the design of premarket trials in Europe and number of patients exposed, but failed as this information is not made public.
Furthermore, the Helsinki Declaration is not followed with respect to the registration and publication of premarket trials.
Conclusions: For innovative high-risk devices, new EU legislation should require the premarket demonstration of clinical efficacy and safety, using an RCT if possible, and a transparent clinical review,
preferably centralized.
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when they enter the market in Europe. At the same time, a
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The clinical review of high-risk medical devices
randomized controlled trial (RCT) is often initiated as a re-
quirement for obtaining market access in the United States.
These RCTs are sometimes partly conducted in Europe with
CE (Conformite´ Europe´enne) marked products (9;19). Simi-
lar observations were made in three rapid assessments by the
Belgian Health Care Knowledge Centre (KCE), covering per-
cutaneous aortic valves, endobronchial valves and interspinous
devices (26;30;31). Payers in Europe are placed in a difficult sit-
uation. Postponing the reimbursement decision until the RCT
results are available is oftenmet with mixed feelings by industry
and clinicians. For the patient, the current system in Europe can
mean earlier access to a potentially lifesaving device, but at the
risk of insufficiently documented efficacy and safety. Further-
more, the cost of the device may be fully charged to the patient.
This growing tension between early market introduction and the
reimbursement of innovative high-risk devices in Europe led us
to take a closer look at the premarket clinical evaluation of such
devices.
Both in Europe and the United States, medical devices are
categorized into different classes based on the risk they pose
to patients, with class III devices representing the highest risk
category. We define innovative high-risk devices in Europe as
class III devices and implantable devices, that differ more than
slightly from existing devices in the same indication with regard
to design, expected effectiveness, or both. In addition, the use of
a high-risk device (new or existing) in a new indication has also
to be considered an innovation. In the United States, innova-
tive high-risk devices (class III) typically undergo a premarket
approval (PMA) process.
Contrary to what health professionals and users of high-risk
medical devices may assume, the premarket clinical evaluation
of high-risk medical devices in Europe is not comparable to the
evaluation of pharmaceuticals in terms of safety and efficacy.
Patient safety aspects of the European approach for high-risk
devices have not been widely discussed in peer reviewed jour-
nals. During the finalization of our study, a policy report by the
European Society of Cardiology was published (13), as well as a
series of articles in the British Medical Journal (4;12;14;28;32)
that call for more transparency and a higher quality clinical
evaluation of medical devices in Europe during both pre- and
postmarketing.
The aim of this study was to review and discuss the premar-
ket clinical evaluation of innovative high-risk medical devices
in Europe and to compare it with evaluations in the United
States. We also compare the evaluation of devices with the eval-
uation of medicines, where appropriate. In addition, we discuss
issues regarding patient safety and the transparency of infor-
mation. This report does not cover the preclinical evaluation or
the manufacturing practices of devices. Furthermore, our con-
clusions should not be extrapolated to the vast number of lower
risk devices outside the scope of this study. The full KCE report
(number 158) on which this manuscript is based is available at
www.kce.fgov.be.
METHODS
We consulted the peer reviewed literature using a Medline
search. The yield of this search was very poor, at least for
descriptions and critical reviews of the European system when
compared with the United States.
We consulted experts of member organizations of EU-
netHTA (aEuropean network ofHTAagencies), andwe checked
the grey literature and European andU.S. regulatory documents.
Furthermore, representatives from Competent Authorities, the
U.S. Food and Drug Administration (FDA), Ethics Committees,
and the Medical Device Industry were consulted.
Three major Notified Bodies were requested by Belgian
Competent Authorities to complete a simple questionnaire on
the number of patients exposed to the innovative device pre-
CE mark and on the type of trial design (randomized or not).
This information (without identifying the device) was requested
for cardiovascular implantable devices with or without an ac-
tive substance and for other implantable devices with an active
substance.
The list of study protocols reviewed byBelgian Ethics Com-
mittees in 2010 was searched for trials with high-risk medical
devices by Professor Marc Bogaert, Belgian Advisory Com-
mittee on Bioethics. In addition, the Ethics Committees were
requested to provide the regulatory status of the device under
study.
Clinical Development Phases
The clinical development of medical interventions and tech-
nologies for a given indication is characterized by different
phases. Exploratory studies, often generating a hypothesis, are
followed by confirmatory studies to test the hypothesis (17).
This phased approach is now the standard for the premarket
clinical development of pharmaceuticals. Exploratory trials of
high-risk devices are more complex compared with drug trials:
it is not just the device itself that is studied but the complete
system. This includes the most optimal procedures for handling
the device and ways of shortening the learning curve. In addi-
tion, exploratory device trials often lead to minor modifications
of the new device, a phenomenon that makes it even more diffi-
cult to determine when an innovation is ready for confirmatory
studies.
Randomized control trials (RCTs) are the highest standard
for documenting clinical safety and demonstrating any incre-
mental efficacy, also for devices. For example, in the absence
of well-controlled trials, it may be impossible to judge whether
a 30-day mortality rate of 5 or 10 percent after the implantation
of a percutaneous aortic valve should be considered high or low
(30). High quality RCTs can also be conducted with devices,
even if these trials involve no or only the partial blinding of
patients, physicians, or outcome assessors (14). Experience at
the FDA has shown that valid and realistic study designs are
possible for the controlled evaluation of the efficacy and safety
of medical devices. The FDA considers RCTs to be critical for
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Table 1. The sequence of clinical development and timing of the market introduction of novel invasive high-risk devices in Europe and the US
Theoretical sequence over time
Confirmatory clinical
Exploratory clinical trials trials (RCTs) Health technology assessment
CE mark system in Europe Market introduction based on single-arm trials
demonstrating safety and “performance”
Requires safety and efficacy/effectiveness data
for the assessment, which may include an
evaluation of cost-effectiveness
FDA PMA process in the US Market introduction based on RCTs
demonstrating safety and
“efficacy/effectiveness”
statistical validity, and they are ethical if designed according to
current U.S. Good Clinical Practice. Randomized controlled tri-
als with sham (or placebo) surgery as a comparator for proving
device efficacy may sometimes be considered unethical. It may
be more appropriate to document efficacy versus the reference
treatment (watchful waiting, another device, drug treatment,
conventional surgery, etc.). To not expose too many patients un-
necessarily to a high-risk intervention, the conduct of an RCT
should not be delayed. This was recently illustrated for stents
used to treat intracranial arterial stenosis, where the stents had
been approved 6 years previously based on a humanitarian de-
vice exemption and on the registry data of only forty-five pa-
tients. After thousands of patients received the device, an RCT
was stopped early because the 30-day rate of stroke or deaths
was significantly higher than after medical treatment (3).
Different Systems of Premarket Clinical Evaluation in Europe and the
United States
The premarket regulations of the FDA and Europe remain very
different despite the creation of a Global Harmonization Task
Force (GHTF) for device regulations in 1992 (www.ghtf.org)
(18).
The European system is based on the demonstration of
safety and performance, whereas the U.S. system requires the
premarket demonstration of safety and efficacy/effectiveness
(Table 1). This leads to entirely different clinical trials. For the
demonstration of device performance, an RCT is neither nec-
essary nor appropriate, whereas it is essential for the demon-
stration of clinical safety and efficacy in a controlled way. The
level of study evidence required in Europe is also much less
specified compared with the FDA requirements for a PMA ap-
plication. The net result is an earlier market introduction in
Europe compared with the United States.
Demonstration of Device Performance in Europe
In Europe, novel high-risk medical devices do not undergo a
premarket review by Member States or European Authorities.
Instead, they have to go through a system of CE (Conformite´
Europe´enne) marking, which is mainly based on the 1993 Med-
ical Device Directive, which was amended in 2007.
Conformite´ Europe´enne marking for high-risk novel med-
ical devices is applied for by the manufacturer and the con-
formity assessment is checked by a Notified Body. Notified
Bodies are for-profit organizations certified by a Member State
Competent Authority. The latter vary between Member States.
In some cases, national medicines agencies are endowed with
the overview of medical devices; in other cases, specific agen-
cies have been set up and, finally, some Member States do not
have any specific pathway for the approval of medical devices,
relying purely on Notified Bodies.
This premarket evaluation of a device by a Notified Body is
performed only once for the entire European market. It includes
the assessment and verification of the clinical evaluation, de-
fined as the assessment and analysis of clinical data pertaining
to a medical device to verify the clinical safety and performance
of the device when used as intended by the manufacturer. It is
very important to note that an evaluation of clinical efficacy is
not part of the premarketing evaluation in Europe.
Member States can invoke a safeguard clause if evidence
of a major public health concern is identified. In the case of
devices containing a human blood derivative, the Notified Body
can only decide positively if the European Medicines Agency’s
scientific opinion is favorable (18). However, for drug-device
combination products, the Notified Body can overrule the opin-
ion of the Medicines Agency.
There are approximately eighty Notified Bodies currently
designated for a total of thirty-one countries in the European
Economic Area (EEA). Some Notified Bodies only have two or
three staff (4). Notified Bodies are not on a level playing field
in terms of their criteria for approval; companies can work with
different Notified Bodies for different devices and Competent
Authorities are aware that companies could select a Notified
Body that is likely to be less stringent in the assessment of a
particular device (4;29). The Notified Body Operating Group
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(http://www.nbog.eu/) is working on this issue and the ongoing
revision of the device directives is expected to provide a solu-
tion (5).
Directive 2007/47/EC, effective from March 2010, states
that, in the case of implantable devices and class III devices,
clinical investigations shall be performed unless reliance on
existing clinical data is duly justified (27). Since May 2011,
all clinical investigations (protocol title and primary objective
only) are entered into a nonpublic database (Eudamed) by the
Competent Authority where the trial is notified first (8); how-
ever, the trial authorization procedure differs significantly by
Member State. Some Competent Authorities actively review
the documentation submitted, including the trial design. Other
Member States, however, have opted for the passive permission
route (no review).
The December 2010 MEDDEV 2.7/4 guidelines (7) do not
provide any specific requirements regarding the depth and extent
of premarketing clinical evaluations of high-risk devices. The
RCT design is not specifically endorsed.
Premarket Clinical Trials in Europe Are not Made Public
Based on grey literature (29) and informal contacts within Com-
petentAuthorities, it seems that the number of patients evaluated
in premarket trials in Europe varies by the indication but is typi-
cally less than 100 patients. These studies are often referred to as
single-arm “feasibility” trials or “performance” trials. Only for
drug-eluting stents is the minimum number of patients exposed
in the premarket phase more or less in the public domain: based
on the potential safety issues that were identified, the number
of patients studied increased over time from 50 to 300 (no RCT
required).
Different initiatives to obtain more information on premar-
ket clinical data did not succeed. BelgianCompetentAuthorities
received no answer from three large Notified Bodies asked to
provide the numbers of patients exposed and the trial design
used for the novel high-risk devices they had approved. In the
UK, researchers failed to obtain premarket clinical data from the
manufacturers and six Notified Bodies for 192 recalled devices
(15;28). Only four companies (2 percent) provided any clinical
data. In the Netherlands, Competent Authorities encountered
difficulties in obtaining technical documentation of class III de-
vices from industry (coronary stents, total hip implants, and
silver-containing wound dressings) (23). It is of interest to note
that even Competent Authorities have to rely on a Google in-
ternet search to identify the class III devices being marketed as
there was (and still is) no comprehensive list or database. Major
shortcomings were identified in the documentation received, in
particular concerning the clinical evaluation of the device (23).
Confidentiality seems to overrule transparency in Europe much
more than in the United States (4).
Based on a large subset of protocols that were reviewed in
2010, representatives of Belgian Ethics Committees reported
that nearly all trials with high-risk devices in Belgium are con-
ducted after the CE mark has been obtained, and that the iden-
tified pre-CE mark trials were not randomized.
Premarket Clinical Review in the United States
In the United States, premarket device review procedures were
introduced in 1976. The evaluations are performed by the
FDA, mainly by its Center for Devices and Radiological Health
(CDRH). For many devices entering the U.S. market the “pre-
market notification” route, the 510(k), applies. Innovative high-
risk medical devices, however, are, in principle, subject to
a more stringent procedure called the “premarket approval”
(PMA) procedure, which typically requires the conduct of a
randomized controlled trial (16).
Under the PMA process each manufacturer must indepen-
dently demonstrate “reasonable assurance of the safety and
effectiveness” of its device for its intended use. To start re-
search trials in the United States to be included in a PMA,
the sponsor first needs to obtain an Investigational Device Ex-
emption (IDE) approval from the FDA (24). For diseases or
conditions affecting small patient populations (under 4,000
patients in the United States), the FDA, since 1996, has al-
lowed Humanitarian Device Exemption (HDE) applications,
which are similar in both form and content to a PMA appli-
cation, but are exempt from the effectiveness requirements of a
PMA.
Nevertheless, PMA applications have been criticized as
they often contain only a single study or they lack adequate
strength or coverage of specific study populations (6;16;20). Re-
cent high-profile cases involving potentially dangerous defects
in widely used cardiovascular devices have increased concerns
about the adequacy of premarket trials and postmarket surveil-
lance for establishing the safety of these devices. Furthermore,
the 510(k) process has also been the subject of debate. A 2011
report by the U.S. Institute of Medicine (www.iom.edu) called
for a new regulatory framework using a risk-based approach to
replace the 510(k) process (2).
Other Effects of the Difference in Systems
Another poorly documented effect that might be linked to the
difference in regulatory systems is that only one in five of the
8,500 medical device companies in Europe (probably fewer if
one excludes the companies belonging to a U.S. group) has
approached the U.S. market (1). In addition, more devices of
a particular type are often marketed in Europe compared with
the United States; for example, 28 drug-eluting stents are CE
marked whereas only 5 have obtained FDA approval. Unfortu-
nately, final negative decisions on PMA dossiers are not made
public on the FDA Web site. Therefore, the possibility that
devices continue to be marketed in Europe even though they
failed to demonstrate efficacy and safety in the RCT required
in the context of a PMA in the United States cannot be ex-
cluded. This is illustrated by the negative FDA panel vote for
an endobronchial valve system in 2008 (10). Several similar
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Table 2. Transparency of trials and their results for devices and pharmaceuticals in Europe and the US
Medical Devices Medicines
Europe Trial registry (Eudamed) not public∗ Public trial registry (EudraCT) and results (EPAR)
Trial results not public∗
US Public trial registry and results (clinicaltrials.gov) Public trial registry and results (clinicaltrials.gov)
∗This is in conflict with the Declaration of Helsinki, which is to be respected according to Medical Device Directives.
examples are given in a recent study by Cohen and Billingsley
(4).
Premarket Demonstration of Clinical Efficacy Is Needed in Europe
The discrepancy between the European andU.S. situations high-
lights the need for a significant change in legislation on this
side of the Atlantic. The FDA believes that RCTs are critical
for statistical validity. In a recent report of the World Health
Organization, regulatory agencies were called upon to ensure
that, whenever possible, high quality randomized trials are com-
pleted before granting marketing approval of high-risk medical
devices (33).
Despite the increase in clinical trial activity induced by the
EU Directive 2007/47/EC, the remaining variations in the strin-
gency of clinical reviews both at the level of Notified Bodies
and Competent Authorities do not guarantee patient safety in
a uniform way for EU citizens. Therefore, for innovative high-
risk devices, the future EU Device Directive should go beyond
requiring safety and “device performance” data only to also
requiring premarket data that demonstrate “clinical safety and
efficacy”. It should also be noted that for devices where only
slight modifications were made to an existing device, a short-
ened development cycle may or may not be appropriate. This
needs to be evaluated case by case.
Members of Ethics Committees and Competent Authorities
are often confronted by a lack of clinical research expertise at
small device companies. In addition, Notified Bodies may also
lack the expertise to interpret clinical data and clinical safety
signals (28). In this regard, the European Society of Cardiology
has recommended that independent expert physicians should be
involved in reviewing the decisions of new class III devices (13).
Initiatives to develop international guidance documents for
premarket clinical trials by the type of high-risk device need to
be stimulated (12). Such guidance documents have been proven
to be of value for the more standardized, high quality clinical
development of medicinal products. Not only professional soci-
eties (13) but, ideally, HTA agencies should also be involved in
this activity, for example by proposing study endpoints, which
will be needed for cost-effectiveness evaluations. Such doc-
uments should also further the standardization of evaluations
across Notified Bodies and Competent Authorities. Industry
could benefit if a positive reimbursement can be better planned
and if potential liability risks of entering the market too early
can be reduced.
Instead of trying to streamline a very fragmented system
of Notified Bodies and Competent Authorities, a more straight-
forward way of achieving the goals discussed above could be
to centralize expertise at the European level, as was done for
advanced therapy medicinal products, and as suggested by the
European Society of Cardiology (13). The transfer of evalua-
tion and approval to a centralized body may, however, be more
urgent for innovative high-risk devices than for other lower risk
devices.
Payers in Europe should consider the co-financing of inno-
vative high-risk devices used in premarket clinical trials, pro-
vided that these trials are well-controlled and have clinically
relevant endpoints. This would reduce the financial hurdle for
industry, which primarily comprises small and medium enter-
prises. This system already exists in the United States, where
the Centers for Medicare and Medicaid Services (CMS) reim-
burse the cost of medical devices studied under the IDE if they
meet certain criteria. The level of reimbursement is up to the
cost of a currently marketed, similar product. As for medicines,
specific regulations are needed for devices aimed at very small
target populations.
The Need for More Transparency in Europe
In the United States, since 2007, full transparency is assured
by the obligatory registration of trial protocols and study re-
sults, both for drugs and devices (11). The EU Clinical Trials
Register now also provides protocol-related information to the
public, but only for trials with medicines. The trial results for
new medicines are made public in European Public Assessment
Reports (EPARs). This is in sharp contrast with the approval
system of devices in Europe (28) (Table 2).
There is a clear need for a public trial registry (25) and a
publicly available summary describing the basis for granting
a CE mark (4). Directive 2007/47/EC specifies that all par-
ties involved in the application of directives are bound to ob-
serve confidentiality with regard to all information obtained
in carrying out their tasks (27). The same Directive, how-
ever, also requires that clinical trials respect the Declaration
of Helsinki. This suggests entering the trial in a publicly avail-
able trial registry before the first patient is entered. Negative and
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positive results should be published or otherwise made publicly
available. This requirement of the Directive is clearly not re-
spected in most cases.
The regulations in Europe allow for an early market intro-
duction of high-risk medical devices at a time when the device
cannot yet be considered to have an established indication in
routine clinical use, suggesting that the use could be called ex-
perimental. Often, the confirmatory clinical development phase
is still to be initiated or is ongoing.
European regulations of research ethics (e.g., the Declara-
tion of Helsinki, The European Convention on Human Rights
and Biomedicine, The Clinical Trials Directive) are mainly fo-
cused on clinical trials; however, there seems to be no reason to
grant less protection to patients who are treated with a high-risk
medical device in the experimental phase outside the context of
a trial.
The new premarket procedure should result in an approved
indication for the device and publicly available product doc-
umentation including the full results of all trials. This trans-
parency is required to allow physicians to practice evidence-
basedmedicine, patients tomake an informed decision andHTA
agencies to produce the correct assessment. It may, however, be
appropriate to also study whether or not the rules that protect
innovation need to be improved in view of this transparency
requirement.
Transparency is also required in cases where the inventor
of the device is also the principal investigator in a clinical trial
of the device, a situation that is not unusual (32).
Measures to be Taken at the Member State Level
When awaiting a reworked Medical Device Directive, patient
risk should be minimized at the Member State level by improv-
ing transparency with regard to the available clinical data and by
limiting the market introduction of novel high-risk devices with
minimal clinical data to centers with the necessary expertise.
Preferably, this should be done under an appropriate research
protocol (RCT if possible). This requires the commitment of the
Competent Authorities, the marketing company, the physicians,
and the hospitals.
The impact of HTA is limited as this occurs during the
postmarket phase. Despite HTA reports concluding that evi-
dence is insufficient for justifying reimbursement, marketing of
the device continues and patients may be charged for its cost.
Therefore, the ethical issues associated with the early market
introduction of innovative high-risk devices should be studied
further by the commissions and organizations that provide eth-
ical guidance to physicians and hospitals.
With regard to patient safety of medical devices, the ma-
jor control point in Europe is still postmarketing rather than
premarketing surveillance, as is the case for medicines (18).
Without active analysis, postmarket surveillance often remains
an empty shell and a false reassurance of patient safety. It is
hampered by an ongoing struggle with both under-reporting of
the numerator (the number of adverse events) and a lack of data
about the denominator (the total number of exposures) (21).
These numbers are often lacking for devices (28). In this con-
text, it has been reported that many manufacturers fail to fully
fulfill their legal responsibility to collect product data once their
device is on the market (4). Therefore, the industry statement
that no information is available to suggest that patient safety
in Europe has been compromised needs to be interpreted with
caution (4).
CONCLUSIONS
HTA agencies in Europe are often confronted with a lack of
high-quality clinical evidence when evaluating novel high-risk
devices. We showed that this is linked to the European reg-
ulatory system that allows early market introduction based on
limited clinical data.We recommend that Europe should require
high-quality randomized trials demonstrating clinical efficacy
and safety before granting the marketing approval of innova-
tive high-risk medical devices. To allow physicians to practice
evidence-based medicine, patients to make an informed deci-
sion and HTA agencies to produce the correct assessment, a
major improvement in the transparency of information is also
needed for such devices in Europe.
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